Skip to contentT
Travere Therapeutics, Inc.
T
TVTXTravere Therapeutics, Inc. Q4 2016 · 10-K
Revenue$37.33M$37.33M+22.6% vs Q4 2015 Net Income-$8.60M-$8.60MN/M vs Q4 2015 EPS Diluted-$0.39-$0.39N/M vs Q4 2015 Operating Income-$18,222,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Travere Therapeutics, Inc. · CIK 1438533 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$9,860,000N/M Margins · derivedOperating margin-48.8%+1.1 pt vs Q4 2015
Net margin-23.0%−14.9 pt vs Q4 2015
ended Dec 31, 2016 · filed Mar 1, 2017 · 60 d after period end